ALK and non-small cell lung carcinoma: A phase I/II trial of alectinib in crizotinib‐refractory ALK‐positive NSCLC included 16 patients with baseline measurable CNS disease, at the time of analysis, showed 4 (25%) of 16 patients had achieved a complete CNS response and 8 (50%) had achieved a partial response, Median duration of CNS response was 11.1 months (95% CI: 5.8–11.1).